- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (11)
23 result(s) found for: Arabinoside.
Displaying page 1 of 2.
EudraCT Number: 2006-002251-33 | Sponsor Protocol Number: 01 | Start Date*: 2006-10-10 |
Sponsor Name:University of Vienna | ||
Full Title: Hypoxia Imaging with the novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic impact in Cervical Cancer . | ||
Medical condition: Twenty-five patients with cervical carcinoma (T2Nx or TxN1) will be included in the present study. In addition to the routine pre-therapeutical staging of cervical cancer, 18FAZA PET will be perfor... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-010114-30 | Sponsor Protocol Number: D1531C00009 | Start Date*: 2009-06-23 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A randomised, open-label, multi-centre, 2-stage, parallel group study to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) i... | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) FR (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004956-60 | Sponsor Protocol Number: UCL/08/0121 | Start Date*: 2009-08-14 | ||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||
Full Title: Phase II Study of Reduced Intensity Allogeneic Transplantation for Refractory Hodgkin Lymphoma | ||||||||||||||||||
Medical condition: Refractory Hodgkin Lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005278-40 | Sponsor Protocol Number: ABR-55752 | Start Date*: 2016-11-29 | |||||||||||
Sponsor Name:Radboudumc | |||||||||||||
Full Title: Molecular imaging before and during (chemo-) radiotherapy in patients with locally advanced Head and Neck, thoracic and pelvic tumors: prognostic and predictive value of 18F-fluoroazomycin arabinos... | |||||||||||||
Medical condition: Head and neck squamous cell carcinoma (HNSCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004661-15 | Sponsor Protocol Number: CLI-037 | Start Date*: 2005-05-17 |
Sponsor Name:Vion Pharmaceuticals, Inc. | ||
Full Title: A Phase III Randomized Study of CLORETAZINE™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients with Acute Myeloid Leukemia in First Relapse | ||
Medical condition: Acute Myeloid Leukemia (AML) in First Relapse | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) DE (Temporarily Halted) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005052-37 | Sponsor Protocol Number: BRAVO | Start Date*: 2021-04-01 | ||||||||||||||||||||||||||
Sponsor Name:Institute of Mother and Child | ||||||||||||||||||||||||||||
Full Title: Optymalizacja czasu leczenia i dawkowania wemurafenibu u małoletnich pacjentów z opornymi na konwencjonalną terapię rozrostami z komórek histiocytarnych z obecnością mutacji w genie BRAF. | ||||||||||||||||||||||||||||
Medical condition: histiocytic cell proliferation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: PL (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005053-25 | Sponsor Protocol Number: TRAM | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
Sponsor Name:Institute of Mother and Child | ||||||||||||||||||||||||||||
Full Title: Optimalization Of The Time And Dosage Of Trametinib In BRAF Negative Juvenile Patients With Refractory Histiocytosis Or After Failure Of Vemurafenib Treatment. | ||||||||||||||||||||||||||||
Medical condition: histiocytic cell proliferation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: PL (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004912-28 | Sponsor Protocol Number: EORTC06061 | Start Date*: 2012-02-17 | ||||||||||||||||
Sponsor Name:European Organisation for Research and Treatment on Cancer | ||||||||||||||||||
Full Title: Clofarabine in combination with a standard remission induction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukem... | ||||||||||||||||||
Medical condition: Previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-007553-31 | Sponsor Protocol Number: AMLSG10-07 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Phase I/II Clinical Study of SU11248 (Sutent) combined with Standard Chemotherapy with Cytosine Arabinoside and Daunorubicin in Patients with FLT3 mutated AML over 60 years of age | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003103-12 | Sponsor Protocol Number: AML-CG2008 | Start Date*: 2009-03-10 | |||||||||||
Sponsor Name:Hospital of the University of Munich | |||||||||||||
Full Title: A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus Standard Double Induction for Initial Chemotherapy ... | |||||||||||||
Medical condition: Adult patients (≥18 years) with newly-diagnosed acute myeloid leukemia (AML) - except acute promyelocytic leukemia (APL) and t(15;17) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003353-16 | Sponsor Protocol Number: GS-US-339-1559 | Start Date*: 2017-04-18 |
Sponsor Name:Gilead Sciences, Inc | ||
Full Title: A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (AML) | ||
Medical condition: Acute Myeloid Leukemia (AML) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001628-72 | Sponsor Protocol Number: P001317 | Start Date*: 2017-07-18 |
Sponsor Name:Medical Center - University of Freiburg | ||
Full Title: Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients | ||
Medical condition: Primary central nervous system lymphoma (PCNSL) is an aggressive Non-Hodgkin Lymphoma (NHL) mostly of B-cell origin, which exclusively invades the central nervous system compartment. It accounts fo... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001789-41 | Sponsor Protocol Number: ET18000120 | Start Date*: 2019-07-16 |
Sponsor Name:Centre Léon Bérard | ||
Full Title: Trial Of Imatinib After Ponatinib Induction (Tipi) - A multicentre, open label phase II trial evaluating the safety and efficacy of ponatinib induction followed by imatinib maintenance in adult pat... | ||
Medical condition: Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), all risk scores, ≤65 years | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001181-10 | Sponsor Protocol Number: P003077 | Start Date*: 2023-04-13 |
Sponsor Name:Medical Center - University of Freiburg | ||
Full Title: Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a rand... | ||
Medical condition: Primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare lymphoma affecting only the central nervous system compartment. PCNSL patients are typically 60 years or older ... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005493-10 | Sponsor Protocol Number: MB-106 | Start Date*: 2022-03-22 | |||||||||||
Sponsor Name:Moleculin Biotech, Inc. | |||||||||||||
Full Title: Phase 1/2 Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML). | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002743-89 | Sponsor Protocol Number: S0106 | Start Date*: 2007-04-10 | |||||||||||
Sponsor Name:Southwest Oncology Group (SWOG) | |||||||||||||
Full Title: A PHASE III STUDY OF THE ADDITION OF GEMTUZUMAB OZOGAMICIN (MYLOTARG®) DURING INDUCTION THERAPY VERSUS STANDARD INDUCTION WITH DAUNOMYCIN AND CYTOSINE ARABINOSIDE FOLLOWED BY CONSOLIDATION AND SUBS... | |||||||||||||
Medical condition: Previously untreated de novo acute myeloid leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000620-17 | Sponsor Protocol Number: DRKS00005503 | Start Date*: 2014-04-28 |
Sponsor Name:Landeshauptstadt Stuttgart, represented by the Executive Medical Director Klinikum Stuttgart | ||
Full Title: High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trial | ||
Medical condition: Primary CNS lymphoma (PCNSL) accounts for 1 to 2% of all Non-Hodgkin's lymphomas (NHL) and for 2 to 7% of all primary CNS tumors. It's incidence has increased over the past 30 years, particularly i... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) DK (Completed) NO (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004503-11 | Sponsor Protocol Number: DACO-016 | Start Date*: 2006-09-14 | ||||||||||||||||
Sponsor Name:Eisai Medical Research Inc. | ||||||||||||||||||
Full Title: Randomized Phase 3 Trial of Decitabine Versus Patient's Choice with Physician's Advice of Either Supportive Care or Low-dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acut... | ||||||||||||||||||
Medical condition: Acute Myloid Leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) ES (Completed) CZ (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000929-32 | Sponsor Protocol Number: JCAR017-BCM-003 | Start Date*: 2018-08-21 | ||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||
Full Title: A global randomized multicenter Phase 3 trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressi... | ||||||||||||||||||
Medical condition: Transplant-eligible relapsed or refractory (R/R) aggressive B-cell Non Hodgkin Lymphoma (B-NHL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) BE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) SE (Completed) NL (Ongoing) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-004891-28 | Sponsor Protocol Number: HM08 / 8451 | Start Date*: 2009-09-03 | ||||||||||||||||
Sponsor Name:Leeds Teaching Hospitals Trust | ||||||||||||||||||
Full Title: Pilot safety/tolerability study of Lenalidomide administered as monotherapy and in combination with standard chemotherapy for Acute Myeloid Leukaemia/high-risk myelodysplastic syndrome with structu... | ||||||||||||||||||
Medical condition: Acute myeloid leukaemia / high-risk Myelodysplastic Syndrome with structural abnormalities of chromosome 5 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
